 |
The history of Corgenix
Medical Corporation shows a strong and sustained commitment to innovation in the
medical healthcare field. From our establishment as REAADS Medical Products in
1990 and subsequent launch of the first commercial kit for the detection of
anticardiolipin antibodies, we have maintained a tradition of being at the forefront of the
medical industry.
|
| 2007 |
| Corgenix Signs Licensing Agreement and Gains
Full Rights to AspirinWorks® Aspirin Response Test |
| Corgenix Receives Second US Patent on AtherOx™
Technology |
| 2006 |
| Corgenix Submits FDA Premarket Notification of
AspirinWorks® Test Kit |
| Corgenix Expands Operations in United States and
Europe |
| Corgenix Launches Diagnostic Test for Aspirin
Effectiveness |
| Corgenix Submits 510K Filing for AtherOx™ |
| Corgenix and Rebio Gen, Inc. Sign Extension To
Technology Agreement for Hyaluronic Acid |
| Corgenix Executes Private Placement Agreement
Representing Initial Gross Proceeds of $3.36 Million |
| 2005 |
| Corgenix Announces Establishment of
Bio-Terrorism Defense Development Program |
| Corgenix Announces Termination of its Proposed
Merger with Genesis Bioventures, Inc. |
| 2004 |
| Corgenix Medical Corporation and Genesis
Bioventures announce signing of merger agreement and completion of $2
million initial financing round. |
| Corgenix and Autoimmune Technologies complete
development of diagnostic product for fibromyalgia. Test kit for
anti-polymer antibodies (APA) to be launched this year through Corgenix
distribution organization. |
| Collaboration of Aspirin Resistance Testing
announced by Corgenix Medical Corporation, Creative Clinical Concepts,
Inc. and McMaster University. Technology used to determine a
patient's response to aspirin therapy taken to prevent heart attacks. |
| 2003 |
| Corgenix announces signed letter of intent to
merge with Genesis Bioventures, Inc. |
| Corgenix receives FDA clearance to market 11
diagnostic tests for risk of cardiovascular disease. |
| 2002 |
| Corgenix signs significant license agreement
which provides Corgenix with exclusive license to new lipid technology
with clinical importance in cardiovascular disease. |
| Corgenix receives updated ISO and EN
certification |
| Corgenix announces $500,000 strategic investment
by Medical and Biological Laboratories, Co. |
| Corgenix and Genesis Bioventures announce
collaboration to develop and commercialize breast cancer test |
| Corgenix effects 1 for 5 reverse stock split and
begins trading under new symbol, CONX. |
| Corgenix signs distribution agreement with
RhiGene, Inc., a wholly owned subsidiary of Medical and Biological
Laboratories Company, Ltd., ("MBL") of Nagoya, Japan which
grants Corgenix exclusive rights to distribute MBL's complete diagnostic
line of autoimmune testing products. |
| Corgenix enters into comprehensive strategic
partnership with Affinity Biologicals, Inc. of Ontario, Canada in the
vascular disease diagnostics market segment. |
| Corgenix enters into collaboration with Genesis
Bioventures, Inc., ("GBI") to develop in ELISA format, products
from GBI's patented Mammostatin Serum Assay ("MSA") for breast
cancer risk assessment. |
| Corgenix Receives a $500,000 strategic
investment by MBL in a continued effort to extend the market opportunities
for MBL's complete diagnostic line of autoimmune testing products
throughout the world. |
| Corgenix receives EN ISO 9001: 1994, EN ISO
46001: 1996, and EN ISO 13485: 2000 certification. |
| Corgenix establishes relationship with
Ascendiant Capital Group, LLC for strategic guidance and support services
in international business development, particularly China and
Brazil. |
| Corgenix reports record revenues from core
business for the fiscal year ended June 30, 2002. |
| Corgenix signs significant license agreement
with Eiji Matsuura, PhD of Okayama University in Okayama, Japan, providing
Corgenix with exclusive license to new lipid technology with clinical
importance in cardiovascular disease. |
| Corgenix recognized in Deloitte & Touche
"Fast 50" program, ranking the 50 fastest growing technology
companies in the state of Colorado for the period 1997-2001. |
| 2001 |
| Corgenix adds Chief Financial
Officer and two highly respected outside Board members to strengthen its
management team.
|
Corgenix receives the country’s first FDA clearance
for two new anti-Prothrombin diagnostic tests. These tests assess the risk for certain cardiovascular disorders characterized by
blood clot formation (thrombosis).
|
Corgenix receives worldwide (excluding Japan) rights to Chugai Pharmaceutical
Company’s intellectual property to manufacture and market a key diagnostic test that
measures hyaluronic acid (HA), a unique indicator of liver
disease and arthritis.
|
Corgenix files a 510(k) Pre-market Notification submission to the US Food and
Drug Administration (FDA) for market clearance of HA in patients with Rheumatoid Arthritis.
|
For the Fiscal Year ended June 30, 2001, Corgenix reports record revenues of
$4.23 million and record net income of $296,000.
|
|
2000 |
| To improve efficiency and better serve the future needs of its expanding
worldwide distribution network and customer base, Corgenix re-aligns its UK
operations to assume direct responsibility for all European, African and Asian
business. In addition, Corgenix signed a new distribution agreement with
Carter-Wallace, Inc, a New York based company and Orinon Diagnostica, a Finnish
medical company to market certain diagnostic products through the United
Kingdom.
|
| Corgenix receives
FDA clearance to market their test kit to detect IgA antibodies to
phosphatidylserine, a laboratory diagnostic test to aid in the diagnosis and
risk assessment of blood clotting disorders. The addition of this test allows
Corgenix to market the most complete line available of immunological tests for
antiphospholipid syndrome.
|
|
1999
|
|
Corgenix
completes a major expansion of its worldwide distribution network by
establishing agreements with healthcare companies in South America, Australia,
New Zealand and India.
|
|
Corgenix
continues its focus on product and organization excellence by receiving ISO 9001
certification, the international standard for quality management systems to
facilitate global commerce.
|
|
Corgenix
introduces four test kits to aid in the diagnosis and risk assessment of blood
clotting disorders. The new tests include assays to detect antibodies to Beta 2
Glycoprotein I and a Monoclonal Free Protein S Antigen test kit.
|
|
1998 |
| REAADS Medical Products merges with Grey Wolf Technologies to form
Corgenix Medical Corporation. Form 10-SB is filed and accepted by the SEC and
shares begin publicly trading over the counter using the symbol: COGX. |
|
1997 |
| REAADS launches three new diagnostic products to aid in the diagnosis of
vascular diseases: Protein C, Protein S and von Willebrand Factor.
|
|
Diagnostic test
kits for Hyaluronic Acid and CETP are launched in the United Kingdom.
|
| 1996 |
| REAADS Medical Products establishes REAADS UK, Ld. with offices in
Peterborough, UK.
|
| REAADS expands its facility in Westminster, Colorado to 12,000 square
feet.
|
| 1995 |
| REAADS releases two new diagnostic kits for worldwide distribution: IgG
aPS and IgM aPS.
|
|
In conjunction
with Chugai, Hyaluronic Acid diagnostic test kits are launched in Japan.
|
| 1994 |
| REAADS establishes a strategic relationship with Cambridge Life Sciences,
a division of Byk Gulden, located in Cambridge, UK., and a leading manufacturer
of immunology and microbiology diagnostic tests.
|
| 1993 |
| REAADS establishes a joint development, manufacturing and distribution
agreement with Chugai Diagnostics Science, Co. Ltd. a wholly owned subsidiary of
Chugai Pharmaceutical Co., Ltd., a Tokyo based company.
|
| REAADS forms a
strategic relationship with Helena Laboratories a world market leading in
clinical electrophoresis instrumentation and technology located in Beaumont,
Texas.
|
| 1992 |
| REAADS introduces the first commercially available IgA anticardiolipin
for worldwide distribution. |
| REAADS expands
its diagnostic product line with the launch of the antinuclear antibody screen
test kit.
|
| REAADS increases
its ability to expand the company product line with agreements with Sigma
Diagnostics, Schiapparelli BioSystems, and BioPool International.
|
| 1991 |
| The rapid growth of business with the launch of REAADS in 1990
necessitates an increase in facility size by 100% to a total area of 7,200
square feet.
|
| 1990
|
| REAADS Medical Products, Inc. is established as a Delaware corporation
and opens for business on August 15, 1990 in Boulder, Colorado.
|
| REAADS launches
five diagnostic test kits to aid in the diagnosis of various autoimmune and
vascular diseases. Kits include IgG anticardiolipin, IgM anticardiolipin, anti
double-stranded DNA, anti-Sm, and Extractable Nuclear Antigen tests kits.
|
| REAADS relocates to Westminster, Colorado.
|
| In order to
expand sales base, REAADS forms a strategic agreement with Sanofi Diagnostics
Pasteur, a leading manufacturer of medical diagnostic kits located in Chaska,
MN. |
